Today BioPorto became aware of market rumours that the company's divisional cut-off patent application no. EP2128625 has been rejected by the European Patent Office (EPO).
These rumours are not true. As part of the normal patent application processing, the EPO has submitted a so-called “Office Action” to BioPorto, requesting further clarification of a number of circumstances relating to BioPorto's divisional NGAL cut-off patent application.
Accordingly, the application process concerning the divisional NGAL cut-off patent will continue according to standard EPO procedures.
Further details from:
Peter Mørch Eriksen, CEO
Phone 45 29 00 00, mail investor@bioporto.com
